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FRoM Phase II studIes to hta subMIssIons: oPtIMal use oF evIdence 
FoR InFoRMed decIsIons
Karabis A, Papadimitropoulou K, Nikolakopoulos S
Mapi Group, Houten, The Netherlands
An attempt is undertaken to provide a framework for the optimal use of clinical 
evidence in the development of a new treatment; starting from the phase II trial(s) 
results, through the design of phase III trial(s), to the needs of payers and HTA 
authorities. The approach is summarized in 3 steps. First: A systematic literature 
review (SLR) and a subsequent assessment of the feasibility of a network meta-
analysis (NMA) based on the published evidence for existing treatments of interest 
is conducted. The key markets of interest and their HTA guidelines are taken into 
account at this point to define the SLR criteria. Second: By means of simulations 
within a Bayesian framework, the sensitivity of the results of a future NMA, if this 
new treatment is included, can be explored. A distribution of the new treatment’s 
effect sizes can be assumed based on previous phase II trial(s), expert beliefs, and/
or the target product profile. The SLR and the NMA results can inform the phase III 
study design, e.g. regarding the appropriate comparators, outcomes, population and 
duration. These results can also inform an early market access strategy based on 
the estimated relative efficacy of the new treatment compared to other treatments. 
Third: Once the results of the phase III trial(s) are available, a well-designed SLR and 
NMA can be easily updated and used for the HTA submissions, with the appropriate 
adaptations per country. The proposed process could aid in earlier understanding 
the relative efficacy of a new treatment to the treatments and outcomes of interest, 
and in taking early informed decisions about the clinical development and market 
access strategy. An illustrating example will be provided assuming a new COPD drug 
and its relative efficacy by means of trough FEV1and %SGRQ responders.
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Full econoMIc assessMent oF RotavIRus vaccInatIon usIng the 
health econoMIc caulIFloweR toolbox
Schecroun N1, Li X2, Standaert B2
1Keyrus Biopharma c/o GSK Vaccines, Wavre, Belgium, 2GSK Vaccines, Wavre, Belgium
Many health economic (HE) evaluations have been published on vaccines, but most 
often they use the cost-effectiveness evaluation tool as the method of analysis with 
a focus on quality-adjusted life-years gained. Meanwhile clinical and economic ben-
efits induced by vaccines can go much broader and beyond that unique aspect. We 
developed an approach that helps identifying additional benefits in a more systematic 
way and applied this approach to rotavirus vaccination. The HE Cauliflower toolbox 
is an instrument that explores along 3 axes the economic value of a new interven-
tion regarding its efficacy, the subject impact and the cost, assessing different layers/
florets within each axis. We detail how a comprehensive economic evaluation of 
rotavirus vaccine can be performed with this approach from different perspectives 
(payer, population, patient, government) based on published data. - Efficacy: includ-
ing herd protection results in a higher effectiveness of the vaccine than predicted by 
efficacy data only; drastic reduction in hospitalisation observed in early evaluations 
of the vaccine leads to better hospital Quality of Care (QoC); the former contributes to 
prioritize the vaccine in portfolio optimisation models. - Subject impact: the vaccine 
benefits caregivers (improved quality of life), employers (decrease in absenteeism dur-
ing annual rotavirus epidemic season) and 3rd party payers (less spending on medical 
visit and hospitalisation). - Costs: indirect cost reduction and cost offsets resulting 
from rotavirus disease case reduction and improved QoC are dramatic with rotavirus 
vaccination. Budget optimization indicates the most efficient dosing scheme. Macro-
economic assessment considers better return on investment with higher tax revenue 
for governments. The economic benefit of rotavirus vaccination has been broadened 
with the use of the HE Cauliflower toolbox, indicating many additional areas of benefit 
that are often hidden at launch of the product. This approach is generalizable to any 
vaccine in the market.
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develoPMent oF a PRecIs-2 scoRIng gRId: how PRagMatIc aRe 
PRagMatIc tRIals oF suRgIcal and PhaRMaceutIcal InteRventIons?
Chen G, Ma Q
Costello Medical Singapore, Singapore, Singapore
Objectives: Pragmatic trials should be designed with the aim to maximise applica-
bility of trial outcomes to clinical practice. The PRECIS-2 tool, published in May 2015, 
aims to assist investigators in assessing the pragmatism of trial protocols using a 
scoring scale (1-5) on 9 domains. However, the lack of scoring criteria makes scor-
ing subjective and hinders comparison of trial scores assigned by different users 
of PRECIS-2. We propose a PRECIS-2 scoring grid to assist objective scoring of trial 
protocols or completed studies. MethOds: A scoring grid with criteria for scores 
1 to 5, in each of the 9 domains of PRECIS-2 (‘Eligibility’, ‘Recruitment’, ‘Setting’, 
‘Organisation’, ‘Flexibility: Delivery’, ‘Flexibility: Adherence’, ‘Follow-up’, ‘Primary 
Outcome’ and ‘Primary Analysis’) was constructed by reviewing the scores assigned 
to example trials in the PRECIS-2 publication and by reviewing the subjective 
guidelines provided by the authors. A structured literature review was conducted 
in PubMed (search terms “pragmatic[title] AND trial[title]”) to find pragmatic trials 
from the last 5 years. Studies with a single experimental arm compared to usual 
care, in surgical or pharmaceutical settings were included. Non-patient, behavioural, 
health service delivery, prognostics, diagnostics and exercise studies were excluded. 
Included studies were assessed according to the PRECIS-2 scoring grid. Results: Of 
341 search results, 8 surgical trials and 11 pharmaceutical trials were included. No 
trials were considered ‘very pragmatic’ (score 5) in all 9 domains. ‘Recruitment’ and 
‘Flexibility: Adherence’ were not reported in several studies (3 and 9, respectively). 
On average, surgical trials and pharmaceutical trials were comparable in the degree 
of pragmatism (mean score [SD]: 4.2 [1.0] vs 4.1 [1.0]). cOnclusiOns: Our PRECIS-2 
scoring grid provides a tool for objective evaluation of pragmatic trials. The next 
step should be to validate the scoring grid across more reviewers and to apply the 
grid to a broader range of pragmatic trials.
On the first of June of 2015, it was published legislation that determines the crea-
tion of a National System of Health Technology Assessment (SiNATS) in Portugal, 
with the purpose to obtain an improvement of health status, in line with other 
European systems. Portugal was one of the first countries to officially adopt meth-
odological guidelines for economic drug evaluation studies. When it was first 
published, in 1998, it was established that these guidelines were to be revised once 
the scientific knowledge and the international standards advised it. However, and 
after 16 years of its publication, it was never reviewed. Currently this work is being 
done, as one of the objectives of SiNATS was to overcome the need felt for several 
years to revise these guidelines. In fact, the recently published guideline methods 
for health economic evaluationby EUnetHTA can be useful to this revision. This 
study focus on all the economic evaluation studies for new drugs submitted for 
reimbursement purposes concluded between 2010 and 2014. One of the aim of 
this analysis is to identify the main gaps on the evaluated studies, based on the 
current methodological guideline in order to avoid the problems followed by the 
need for corrections by pharmaceutical companies and consequently the delays 
in the assessment. Furthermore, another focus of this study is to access which 
new topics are now being included in the submitted studies and are not covered 
by the methodological guideline, but have been taken into consideration upon the 
reimbursement decision. Overall, this study intends to contribute to the revision 
of the methodological guidelines, reducing the time and the resources spent on 
the evaluation of the studies instigated by the need to correct the studies that 
were not in line with the guidelines.
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a FRaMewoRk FoR PRIoRItIzIng ReseaRch InvestMents In PRecIsIon 
MedIcIne
Basu A, Carlson JJ, Veenstra DL
University of Washington, Seattle, WA, USA
PuRPOse: The adoption of precision medicine (PM) has been limited in practice to 
date, and yet its promise has attracted research investments. Developing founda-
tional economic approaches for directing proper use of PM and stimulating growth 
in this area from multiple perspectives is thus quite timely. MethOd: Building on 
our previously developed Expected Value of Individualized Care (EVIC) framework, 
we conceptualize new decision-relevant metrics to better understand and forecast 
the expected value of PM. Several aspects of behavior at the patient, physician and 
the payer level are considered that can inform the rate and manner in which PM 
innovations diffuse throughout the relevant population. We illustrate this frame-
work and the methods using a retrospective evaluation of the use of OncotypeDx 
genomic test among breast cancer patients. Result: The enriched metrics can 
help inform many facets of PM decision making, such as evaluating alternative 
reimbursement levels for PM tests, implementation and education programs for 
physicians and patients, and decisions around research investments by manufac-
turers and public entities. We replicated prior published results on evaluation of 
OncotypeDx among breast cancer patients, but also illustrated that those results 
are based on assumptions that are often not met in practice. Instead, we show how 
incorporating more practical aspects of behavior around PM could lead to drastically 
different estimates of value. For OncotypeDx, population returns to a social insurer 
ranged from $17Billions to $37Billion and from $4Billion to $10Billion in revenues 
for the manufacturer depending on the nature of reimbursement policies and dif-
fusion patterns. cOnclusiOn: We believe that the framework and the methods 
presented can provide decision makers with more decision-relevant tool to explore 
the value of PM. There is a growing recognition that data on adoption is important to 
decision makers. More research is needed to develop prediction models for potential 
diffusion of PM technologies.
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valIdatIon oF socIal MedIa analysIs FoR outcoMes ReseaRch: 
IdentIFIcatIon oF dRIveRs oF swItches between oRal and Injectable 
theRaPIes FoR MultIPle scleRosIs
Risson V1, Saini D2, Bonzani I3, Huisman A1, Olson M1
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Objectives: Social media is increasingly used by patient seeking information 
about drugs and has been analysed to understand attitudes, behaviours and per-
ceptions. however the applicability of social-media analysis to adress specific 
questions in outcomes research is largely untested. We analysed the representa-
tiveness of social-media populations and employed social-intelligence method-
ologies to study treatment-switching patterns from/to oral therapies in multiple 
sclerosis (MS). MethOds: A comprehensive listening and analysis process was 
developed which blends automated listening with filtering and analysis of social-
media data by life-sciences qualified analysts and physicians. The population was 
patients with MS from the United States. Data sources were Facebook, Twitter, 
blogs and online forums which were searched for mention of Tecfidera and Gilenya 
as examples of oral MS treatments. Results: A total of 10,260 extracted data 
points were relevant to the objectives and included in the analysis. Women aged 
30-49 and diagnosed for > 10 years were more active on social media platforms 
than other MS patients. The identified population was highly similar to that identi-
fied in MS market research, thus validating the approach. Treatment switches were 
most frequent among patients on injectable therapies: 927 data points described 
patients switching from injectable (mainly BRACE therapies) to oral therapies. 
Side effects were the main reason (25%) for switching to oral therapies. Switches 
away from oral therapies were mostly to non-BRACE injectables in a search for 
greater efficacy. cOnclusiOns: This study of switching patterns in MS treatment 
shows social intelligence analysis to be a powerful method applicable to outcomes 
research. The identified population was representative of the wider population 
when compared with available market research data. Social intelligence was able 
to quantify switching patterns and to identify factors behind switching behaviour, 
which were mostly from injectable to oral therapies, driven by side effects from 
medication.
